Quidel Corporation (QDEL): Price and Financial Metrics
Quidel Corporation (QDEL)
Today's Latest Price: $196.64 USD
Updated Sep 21 11:32am
Add QDEL to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
QDEL Stock Summary
- Price to trailing twelve month operating cash flow for QDEL is currently 43.82, higher than 92.18% of US stocks with positive operating cash flow.
- Over the past twelve months, QDEL has reported earnings growth of 140.73%, putting it ahead of 91.5% of US stocks in our set.
- The volatility of Quidel Corp's share price is greater than that of 90.11% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Quidel Corp, a group of peers worth examining would be APPF, MJCO, LMNX, CPRX, and ECOM.
- QDEL's SEC filings can be seen here. And to visit Quidel Corp's official web site, go to www.quidel.com.
QDEL Stock Price Chart Technical Analysis Charts
QDEL Price/Volume Stats
| Current price | $196.64 | 52-week high | $306.72 |
| Prev. close | $189.31 | 52-week low | $55.25 |
| Day low | $185.43 | Volume | 854,170 |
| Day high | $197.95 | Avg. volume | 944,217 |
| 50-day MA | $224.41 | Dividend yield | N/A |
| 200-day MA | $145.24 | Market Cap | 8.25B |
Quidel Corporation (QDEL) Company Bio
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, womens health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.
QDEL Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $196.64 | $445.65 | 135% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Quidel Corp. To summarize, we found that Quidel Corp ranked in the 64th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 136.5% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for QDEL, they are:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 98. Its equity weight surpasses that of 85.38% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 7.14% of the free cash flow producing stocks we're observing.
- QDEL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.47% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 131% |
| 1% | 133% |
| 2% | 135% |
| 3% | 138% |
| 4% | 140% |
| 5% | 142% |
DVA, AHPI, BKD, HCSG, and PBH can be thought of as valuation peers to QDEL, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...